Physician profile
Walter E Stephens
NPI 1205878220
$10,541.10
in general payments reported to CMS, 2019-2025
47 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $801 · 2021: $1,232 · 2022: $1,684 · 2023: $2,235 · 2024: $1,895 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,138.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,108.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,157.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $929.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $854.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $697.67 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $686.49 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $455.31 | 2022-2025 | |
| Astellas Pharma US INC | $308.57 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $295.08 | 2019-2023 | Xarelto |
| Abbott Laboratories | $266.57 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $239.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.97 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $181.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.36 | 2020-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $168.86 | 2022-2025 | Rexulti |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $143.62 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Mylan Specialty L.P. | $135.70 | 2022-2024 | Yupelri |
| Exact Sciences Corporation | $132.39 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $112.76 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $108.01 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $106.77 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $102.16 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $102.14 | 2025 | Korlym |
| Dexcom, INC. | $97.00 | 2022-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $92.95 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $76.10 | 2023 | Inspire |
| Phathom Pharmaceuticals, INC. | $68.81 | 2024 | Voquezna |
| Shield Therapeutics INC | $52.17 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $46.48 | 2023 | Eliquis |
| Allergan, INC. | $43.65 | 2020-2021 | |
| Nevro Corp. | $40.61 | 2023-2024 | Senza |
| Insulet Corporation | $36.45 | 2022-2023 | Omnipod |
| Eisai INC. | $34.83 | 2024 | |
| Xeris Pharmaceuticals, INC. | $34.77 | 2022-2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $33.62 | 2019 | |
| Halozyme INC | $32.72 | 2023 | |
| Irhythm Technologies, INC. | $25.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.42 | 2020-2021 | |
| Axsome Therapeutics, INC. | $21.36 | 2025 | Auvelity |
| Seqirus USA INC | $20.56 | 2025 | Flucelvax |
| Viatris Specialty LLC | $20.03 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $17.99 | 2023 | Krystexxa |
| Vbi Vaccine (Delaware) INC. | $15.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.12 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $12.75 | 2023 | Contrave |
| Biohaven Pharmaceuticals, INC. | $12.00 | 2021 | |
| Sanofi Pasteur INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.